Spruce Biosciences Reports Positive Long-Term Clinical Data for TA-ERT in Sanfilippo Syndrome Type B, Paving Way for FDA Approval
SPRB has more than doubled off its 52-week low of $4.275 on light trading volume (0.4× avg).
Summary
Spruce Biosciences presented positive long-term clinical data for its TA-ERT in Sanfilippo Syndrome Type B, showing durable reduction of heparan sulfate and preserved cognitive and motor outcomes, positioning it as a potential first-in-class therapy.
Key Events · Product Development and Regulatory · SPRB
-
Positive Long-Term Clinical Data
Spruce Biosciences announced long-term data (up to six years) for tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB), demonstrating rapid and durable reduction of heparan sulfate and preserved cognitive and non-cognitive outcomes.
-
Stabilization of Cognitive and Motor Skills
TA-ERT treatment stabilized cognitive function (Bayley-III Cognitive Raw Score), receptive and expressive communication, and fine and gross motor skills, contrasting with declines observed in untreated natural history patients.
-
Potential First-in-Class Therapy
The company highlights TA-ERT's potential as the first disease-modifying treatment option for MPS IIIB, a fatal condition with no currently approved therapies.
-
Clear Regulatory Path
The data strengthens confidence in advancing the program through a Biologics License Application (BLA) submission and potential U.S. FDA approval, with the possibility of accelerated approval.
Analysis · SPRB · Life Sciences
Spruce Biosciences announced highly significant long-term clinical data for its tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB). The data, presented at a major symposium, demonstrates TA-ERT's potential as the first disease-modifying treatment for this fatal genetic disorder. The sustained normalization of key biomarkers and preservation of cognitive and motor skills over six years, coupled with a favorable safety profile, significantly de-risks the program and strengthens the path towards a Biologics License Application (BLA) submission and potential FDA approval. This positive development is a critical catalyst for the company, given the high unmet medical need and the transformative potential for patients.
At the time of this filing, SPRB was trading at $70.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.8M. The 52-week trading range was $4.28 to $240.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.